Unfortunately, now that it’s March and the Half Year Report has come and gone without any deals, I’ve had to add four new failures to Starpharma’s extensive list of failure milestones:
1 • failure to achieve a licence deal for SN38 in the 0-9 month timeframe as advised in the May 2024 business update.
2 • failure to achieve a licence deal for DEP-Cabazitaxel in the 0-9 month timeframe as advised in the May 2024 business update.
3 • failure to sign a licence deal from the long-established research agreement with Genentech in the 0-9 month timeframe as advised in the 2024 business update.
4 • failure to sign a licence deal from the long-established research agreement with MSD in the 0-9 month timeframe as advised in the May 2024 business update
Add those four brand new failures to the long list below. Just what the hell is going on at Abbotsford HQ?
• Starpharma abandoning its long-established DEP-HER2 ADC program • Starpharma getting asked a for please explain by the MHRA in the UK and temporarily removing Viraleze from the shelves. • The lack of overall commercial success of Viraleze. • Viraleze failing to meet the primary endpoint of the Covid treatment trial. • The TGA refusing marketing approval for Viraleze. • The TGA fining Starpharma for alleged illegal advertising of Viraleze • The ASX asking Starpharma if one of their announcements constituted ramping. • BigPharma saying no thank you to licencing any of the internal DEP drugs for Phase 3 trials. • The extraordinarily delayed results of DEP-Docetaxel (5 years later than originally indicated) • The average Phase 2 trial results of DEP-Docetaxel • The subsequent de-prioritisation of the once flagship DEP-Docetaxel by Starpharma • DEP-Gemcitabine being withdrawn from going into clinical trials at the 11th hour. • The Sky and Land ‘deal’ for condoms in the Chinese Govt sector not going ahead. • Starpharma not commencing any new internal DEP trials since 2019 • The poor sales of VivaGel BV/Fleurstat • The poor performing partnership with Mundiparma that was subsequently terminated • AstraZeneca terminating the Phase One trial for solid cancers • AstraZeneca terminating the Phase One trial for non-hodgkin lymphoma • AstraZeneca terminating the Phase One trial for haematological malignancies • AstraZeneca not taking up the development and option agreement with • Starpharma’s inability to get a BARDA grant for Viraleze in the USA • AstraZeneca deciding that Starpharma’s DEP platform no longer has any collaboration value • The Chase Sun anti-infective program being de-prioritised. • The proprietary condoms turning out to be a dud commercial product. • The once hyped but now shelved SPL7013 viral conjunctivitis opportunity • The non-eventuating Indian Viraleze deal • DEP-Remdesivir never seeing the light of day • The CRL issued to Starpharma by the FDA in 2018 • The subsequent long-running FDA legal saga • Starpharma ultimately failing in its formal dispute with the FDA • No broker coverage of Starpharma • Institutional investor capitulation • SPL being dumped from the ASX300 • SPL later being dumped from the All Ords Index • Starpharma’s glacial-paced early research and pre-clinical Radiopharmaceutical program
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)